Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: A single institution experience

R. Torrisi, C. A. Garcia-Etienne, A. Losurdo, E. Morenghi, L. Di Tommaso, W. Gatzemeier, A. Sagona, B. Fernandes, C. Rossetti, M. Eboli, A. Rubino, E. Barbieri, C. Andreoli, S. Orefice, C. Gandini, S. Rota, M. Zuradelli, G. Masci, A. Santoro, C. Tinterri

Research output: Contribution to journalArticle

Abstract

Purpose: We investigated in a single institution series of 124 women with operable breast cancer whether tumor clinicopathological features could predict the 70-gene signature (Mammaprint®, MP) results, and whether MP results could help to make decisions for the use of chemotherapy (CT) in patients (pts) with ER positive breast cancer beyond recommendations of international guidelines. Results: Among the 68 ER/PgR positive, HER2 negative tumors, Ki-67≥20% was the only significant predictor of a high risk-MP among standard clinicopathological features. In candidates for endocrine therapy with undetermined benefit from CT according to international guidelines, MP results would have led to different treatment decisions in 13/46 (28%) and in 20/68 (29%) pts according to NCCN and St. Gallen recommendations, respectively. Conclusions: Ki-67 independently predicted high risk-MP in ER/PgR positive, HER2 negative tumors. MP results would have led to discordant treatment recommendations in about 30% of cases, generally increasing indication rate for CT. The results of large randomized trials are warranted in order to understand whether we should rely on multigene assays rather than on standard clinicopathological features for treatment decisions.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalBreast
Volume22
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Drug Therapy
Genes
Neoplasms
Guidelines
Breast Neoplasms
Therapeutics

Keywords

  • Adjuvant systemic treatment
  • Breast cancer
  • Mammaprint
  • Multigene signatures
  • Predicting factors
  • Treatment guidelines

ASJC Scopus subject areas

  • Surgery

Cite this

Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors : A single institution experience. / Torrisi, R.; Garcia-Etienne, C. A.; Losurdo, A.; Morenghi, E.; Di Tommaso, L.; Gatzemeier, W.; Sagona, A.; Fernandes, B.; Rossetti, C.; Eboli, M.; Rubino, A.; Barbieri, E.; Andreoli, C.; Orefice, S.; Gandini, C.; Rota, S.; Zuradelli, M.; Masci, G.; Santoro, A.; Tinterri, C.

In: Breast, Vol. 22, No. 4, 08.2013, p. 419-424.

Research output: Contribution to journalArticle

Torrisi, R. ; Garcia-Etienne, C. A. ; Losurdo, A. ; Morenghi, E. ; Di Tommaso, L. ; Gatzemeier, W. ; Sagona, A. ; Fernandes, B. ; Rossetti, C. ; Eboli, M. ; Rubino, A. ; Barbieri, E. ; Andreoli, C. ; Orefice, S. ; Gandini, C. ; Rota, S. ; Zuradelli, M. ; Masci, G. ; Santoro, A. ; Tinterri, C. / Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors : A single institution experience. In: Breast. 2013 ; Vol. 22, No. 4. pp. 419-424.
@article{ab249ff064d948cb812230110254fe7d,
title = "Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: A single institution experience",
abstract = "Purpose: We investigated in a single institution series of 124 women with operable breast cancer whether tumor clinicopathological features could predict the 70-gene signature (Mammaprint{\circledR}, MP) results, and whether MP results could help to make decisions for the use of chemotherapy (CT) in patients (pts) with ER positive breast cancer beyond recommendations of international guidelines. Results: Among the 68 ER/PgR positive, HER2 negative tumors, Ki-67≥20{\%} was the only significant predictor of a high risk-MP among standard clinicopathological features. In candidates for endocrine therapy with undetermined benefit from CT according to international guidelines, MP results would have led to different treatment decisions in 13/46 (28{\%}) and in 20/68 (29{\%}) pts according to NCCN and St. Gallen recommendations, respectively. Conclusions: Ki-67 independently predicted high risk-MP in ER/PgR positive, HER2 negative tumors. MP results would have led to discordant treatment recommendations in about 30{\%} of cases, generally increasing indication rate for CT. The results of large randomized trials are warranted in order to understand whether we should rely on multigene assays rather than on standard clinicopathological features for treatment decisions.",
keywords = "Adjuvant systemic treatment, Breast cancer, Mammaprint, Multigene signatures, Predicting factors, Treatment guidelines",
author = "R. Torrisi and Garcia-Etienne, {C. A.} and A. Losurdo and E. Morenghi and {Di Tommaso}, L. and W. Gatzemeier and A. Sagona and B. Fernandes and C. Rossetti and M. Eboli and A. Rubino and E. Barbieri and C. Andreoli and S. Orefice and C. Gandini and S. Rota and M. Zuradelli and G. Masci and A. Santoro and C. Tinterri",
year = "2013",
month = "8",
doi = "10.1016/j.breast.2013.03.013",
language = "English",
volume = "22",
pages = "419--424",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors

T2 - A single institution experience

AU - Torrisi, R.

AU - Garcia-Etienne, C. A.

AU - Losurdo, A.

AU - Morenghi, E.

AU - Di Tommaso, L.

AU - Gatzemeier, W.

AU - Sagona, A.

AU - Fernandes, B.

AU - Rossetti, C.

AU - Eboli, M.

AU - Rubino, A.

AU - Barbieri, E.

AU - Andreoli, C.

AU - Orefice, S.

AU - Gandini, C.

AU - Rota, S.

AU - Zuradelli, M.

AU - Masci, G.

AU - Santoro, A.

AU - Tinterri, C.

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: We investigated in a single institution series of 124 women with operable breast cancer whether tumor clinicopathological features could predict the 70-gene signature (Mammaprint®, MP) results, and whether MP results could help to make decisions for the use of chemotherapy (CT) in patients (pts) with ER positive breast cancer beyond recommendations of international guidelines. Results: Among the 68 ER/PgR positive, HER2 negative tumors, Ki-67≥20% was the only significant predictor of a high risk-MP among standard clinicopathological features. In candidates for endocrine therapy with undetermined benefit from CT according to international guidelines, MP results would have led to different treatment decisions in 13/46 (28%) and in 20/68 (29%) pts according to NCCN and St. Gallen recommendations, respectively. Conclusions: Ki-67 independently predicted high risk-MP in ER/PgR positive, HER2 negative tumors. MP results would have led to discordant treatment recommendations in about 30% of cases, generally increasing indication rate for CT. The results of large randomized trials are warranted in order to understand whether we should rely on multigene assays rather than on standard clinicopathological features for treatment decisions.

AB - Purpose: We investigated in a single institution series of 124 women with operable breast cancer whether tumor clinicopathological features could predict the 70-gene signature (Mammaprint®, MP) results, and whether MP results could help to make decisions for the use of chemotherapy (CT) in patients (pts) with ER positive breast cancer beyond recommendations of international guidelines. Results: Among the 68 ER/PgR positive, HER2 negative tumors, Ki-67≥20% was the only significant predictor of a high risk-MP among standard clinicopathological features. In candidates for endocrine therapy with undetermined benefit from CT according to international guidelines, MP results would have led to different treatment decisions in 13/46 (28%) and in 20/68 (29%) pts according to NCCN and St. Gallen recommendations, respectively. Conclusions: Ki-67 independently predicted high risk-MP in ER/PgR positive, HER2 negative tumors. MP results would have led to discordant treatment recommendations in about 30% of cases, generally increasing indication rate for CT. The results of large randomized trials are warranted in order to understand whether we should rely on multigene assays rather than on standard clinicopathological features for treatment decisions.

KW - Adjuvant systemic treatment

KW - Breast cancer

KW - Mammaprint

KW - Multigene signatures

KW - Predicting factors

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=84879784816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879784816&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2013.03.013

DO - 10.1016/j.breast.2013.03.013

M3 - Article

C2 - 23643803

AN - SCOPUS:84879784816

VL - 22

SP - 419

EP - 424

JO - Breast

JF - Breast

SN - 0960-9776

IS - 4

ER -